{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:49:59Z","timestamp":1781977799468,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Clinical and Translational Science Awards\/General Clinical Research Center"},{"name":"Baylor College of Medicine","award":["M01RR00188"],"award-info":[{"award-number":["M01RR00188"]}]},{"DOI":"10.13039\/100008136","name":"Case Western Reserve University","doi-asserted-by":"crossref","award":["UL1RR024989"],"award-info":[{"award-number":["UL1RR024989"]}],"id":[{"id":"10.13039\/100008136","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical and Translational Science Institute at Children's National Medical Center NIH\/NCRR","award":["UL1RR31988"],"award-info":[{"award-number":["UL1RR31988"]}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"crossref","award":["UL1RR31973"],"award-info":[{"award-number":["UL1RR31973"]}],"id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007277","name":"Mount Sinai School of Medicine","doi-asserted-by":"crossref","award":["UL1RR29887"],"award-info":[{"award-number":["UL1RR29887"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006668","name":"Oregon Health & Science University","doi-asserted-by":"crossref","award":["UL1RR24140"],"award-info":[{"award-number":["UL1RR24140"]}],"id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"crossref","award":["UL1RR25744"],"award-info":[{"award-number":["UL1RR25744"]}],"id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008090","name":"Tufts University","doi-asserted-by":"crossref","award":["UL1RR25752"],"award-info":[{"award-number":["UL1RR25752"]}],"id":[{"id":"10.13039\/100008090","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"crossref","award":["UL1RR33176"],"award-info":[{"award-number":["UL1RR33176"]}],"id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"crossref","award":["UL1RR25780"],"award-info":[{"award-number":["UL1RR25780"]}],"id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"crossref","award":["UL1RR29890"],"award-info":[{"award-number":["UL1RR29890"]}],"id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"crossref","award":["UL1RR33183"],"award-info":[{"award-number":["UL1RR33183"]}],"id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"crossref","award":["UL1RR24153"],"award-info":[{"award-number":["UL1RR24153"]}],"id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"crossref","award":["UL1TR000005"],"award-info":[{"award-number":["UL1TR000005"]}],"id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"crossref","award":["UL1RR25764"],"award-info":[{"award-number":["UL1RR25764"]}],"id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"crossref","award":["UL1RR25014"],"award-info":[{"award-number":["UL1RR25014"]}],"id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Urea Cycle Disorders Consortium"},{"name":"NIH","award":["U54RR019453"],"award-info":[{"award-number":["U54RR019453"]}]},{"name":"O'Malley Foundation"},{"DOI":"10.13039\/100001204","name":"Kettering Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001204","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ymgme.2013.09.017","type":"journal-article","created":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T20:46:25Z","timestamp":1381265185000},"page":"446-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio"],"prefix":"10.1016","volume":"110","author":[{"given":"M.","family":"Mokhtarani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Rhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Lichter-Konecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Feigenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Berquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"McCandless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Rockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ghabril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"R.S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Moors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Coakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Milikien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Nagamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"LeMons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.F.","family":"Scharschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2013.09.017_bb0005","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.23589","article-title":"Pharmacology and safety of a novel ammonia lowering agents in healthy adults and adults with cirrhosis","volume":"51","author":"McGuire","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0021-9258(18)70632-7","article-title":"A meister, synthesis of phenylacetylglutamine by human tissue","volume":"229","author":"Moldave","year":"1957","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2010.03.014","article-title":"Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: Safety, pharmacokinetics and ammonia control","volume":"100","author":"Lee","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2011.04.013","article-title":"Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate","volume":"103","author":"Lichter-Konecki","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0025","first-page":"1271","article-title":"Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate","volume":"51","author":"Diaz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0030","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jpeds.2012.11.084","article-title":"Ammonia control in children ages 2months through 5years with urea cycle disorders (UCDs); comparison of sodium phenylbutyrate and glycerol phenylbutyrate","volume":"162","author":"Smith","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jcph.92","article-title":"Glycerol phenylbutyrate, a novel investigational ammonia scavenging agent, demonstrated unique behavior based on pharmacokinetic\/pharmacodynamic (PKPD) modeling","volume":"53","author":"Monteleone","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0040","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.ymgme.2003.12.011","article-title":"Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers","volume":"81","author":"MacArthur","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0045","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0021-9258(18)75865-1","article-title":"Further studies on the detoxification of phenylacetic acid","volume":"101","author":"Ambrose","year":"1933","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0021-9258(18)86369-4","article-title":"The maximum production of glutamine by the human body as measured by the output of phenylacetylglutamine","volume":"37","author":"Sherwin","year":"1919","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0055","first-page":"259","article-title":"Toxicity of phenyacetyl acid","volume":"40","author":"Sherwin","year":"1919"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0060","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMoa066596","article-title":"Survival after treatment with phenylacetate and benzoate for urea-cycle disorders","volume":"356","author":"Enns","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1005661631281","article-title":"Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia","volume":"23","author":"Praphanphoj","year":"2000","journal-title":"J. Inherit. Metab."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0070","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI111640","article-title":"Arginine, an indispensable amino acid for patients with inborn errors of urea synthesis","volume":"72","author":"Brusilow","year":"1984","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ymgme.2013.09.017_bb0075","first-page":"290","article-title":"New approaches to the diagnosis and treatment of inborn errors of urea synthesis","volume":"68","author":"Batshaw","year":"1981","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients","volume":"13","author":"Brahe","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","article-title":"Pilot trial of phenylbutyrate in spinal muscular atrophy","volume":"14","author":"Mercuri","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.2002.0639","article-title":"Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate","volume":"6","author":"Zeitlin","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/ajrccm.157.2.9706088","article-title":"A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in \u0394F508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function","volume":"157","author":"Rubenstein","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V85.1.43.bloodjournal85143","article-title":"Oral sodium phenylbutyrate therapy in homozygous thalassemia: a clinical trial","volume":"85","author":"Collins","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V84.1.339.339","article-title":"Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate","volume":"84","author":"Dover","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1203\/00006450-198611000-00011","article-title":"Waste nitrogen excretion via amino acid acylation: benzoate and phenlyacetate lysinuric acid protein intolerance","volume":"20","author":"Simell","year":"1986","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0115","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/1078-0432.CCR-09-0567","article-title":"A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors","volume":"15","author":"Lin","year":"2009","journal-title":"Clin. Cancer Ther."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10637-006-9017-4","article-title":"Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors","volume":"25","author":"Camacho","year":"2007","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0125","first-page":"995","article-title":"Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer","volume":"27","author":"Sung","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.leu.2404050","article-title":"Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Maslak","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00280-003-0674-0","article-title":"Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer","volume":"52","author":"Thompson","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0140","first-page":"963","article-title":"Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia1","volume":"8","author":"Gore","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1592\/phco.21.3.281.34207","article-title":"Phenylacetate pharmacokinetics based on iterative two-stage population analysis","volume":"21","author":"Burstein","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0150","first-page":"3047","article-title":"A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule","volume":"7","author":"Carducci","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0155","first-page":"2330","article-title":"Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia","volume":"7","author":"Gore","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0160","first-page":"2292","article-title":"A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies","volume":"7","author":"Gilbert","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0165","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.1999.17.3.984","article-title":"Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American brain tumor consortium report","volume":"17","author":"Chang","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0170","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/j.1552-4604.1995.tb04075.x","article-title":"Disposition of phenylbutyrae and its metabolites, phenylacetate and phenylacetylglutamine","volume":"35","author":"Piscitelli","year":"1995","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0175","first-page":"2932","article-title":"Phase I study of phenylacetate administered twice daily to patients with cancer","volume":"75","author":"Thibault","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0180","first-page":"1690","article-title":"Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer","volume":"54","author":"Thibault","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0185","article-title":"Randomized, controlled, double blind study of glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy","author":"Rockey","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgme.2013.09.017_or0005","doi-asserted-by":"crossref","unstructured":"M. Ghabril, I.A. Zupanets, J. Vierling, P. Mantry, D. Rockey; D. Wolf et al., Glycerol phenylbutyrate in patients with cirrhosis and hepatic encephalopathy: A pilot study of safety and effect on ammonia, Clin. Pharmacol. in Drug Development (published online March, 2013)","DOI":"10.1002\/cpdd.18"},{"key":"10.1016\/j.ymgme.2013.09.017_rf0220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is stochastically larger than the other","volume":"18","author":"Mann","year":"1986","journal-title":"Ann. Math. Stat."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0200","series-title":"Cambridge Series in Statistical and Probabilistic Mathematics","first-page":"358","article-title":"Bootstrap methods and their application","author":"Davison","year":"1997"},{"key":"10.1016\/j.ymgme.2013.09.017_bb0205","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1471-4159.1984.tb02819.x","article-title":"On the possible mechanism of phenylacetate neurotoxicity: inhibition of choline acetyltransferase by phenylacetyl-CoA","volume":"42","author":"Potempska","year":"1985","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2013.09.017_bb0210","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ymgme.2012.10.009","article-title":"Evidence for the involvement of medium chain acyl dehydrogenase in the metabolism of phenylbutyrate","volume":"107","author":"Kormanik","year":"2012","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213003296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213003296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T15:26:08Z","timestamp":1646753168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719213003296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1096719213003296"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.09.017","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}